Docstoc

Aarkstore.com - Breast Cancer Vaccines and Therapeutic Antibodies- Pipeline_ 2011

Document Sample
Aarkstore.com - Breast Cancer Vaccines and Therapeutic Antibodies- Pipeline_ 2011 Powered By Docstoc
					Aarkstore.com announces, a new market research report is available in its vast collection:


 Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline,
                             2011
http://www.aarkstore.com/reports/Breast-Cancer-Vaccines-and-Therapeutic-Antibodies-Pipeline-
2011-146442.html

Summary

The breast cancer immunotherapy pipeline is showing rapid development. This report presents
findings on more than 30 candidate therapies, including 22 therapeutic vaccines and 11 antibodies. Of
the 22 vaccines in development, 7 (32%) are at clinical phases II – III.

Drugs used to treat breast cancer fall into three main groups: hormonal blockers, chemotherapeutic
agents and targeted antibodies. While these provide important treatment options for patients, their
limitations (drug resistance, poor efficacy and side effects) have focused efforts on developing safer
and more effective targeted therapies. Currently, the greatest growth in this field is in the
development of breast cancer immunotherapies; therapeutic vaccines and antibodies.

This report presents a comprehensive review of the breast cancer immunotherapy pipeline, covering
new candidate vaccines and antibodies. Currently, there are more than 20 candidate breast cancer
vaccines in the pipeline. These include selective candidates, developed to target breast cancer and
others, that are being evaluated against a number of cancer types, including breast cancer. This
report also covers current developments on 11 antibodies, some of which are new molecules
developed to selectively target breast cancer and others, that are being evaluated for a number of
cancers, including breast cancer.

The development of candidate vaccines is seeing significant innovation, as companies establish novel
biological strategies to stimulate the immune system to target antigens associated with breast cancer.
Of the 22 candidate vaccines in development, 7 (32%) are at clinical phases II – III. This report also
includes a technical overview of each of the candidate therapeutic vaccines and antibodies discussed.

The candidates vaccines and antibodies identified in this report target 17 different cancer antigens or
(antibody) drug targets and these developments are being taken forward by 30 different companies.
Of these, 23 (77%) are small and medium-sized organisations or groups, and seven are major
multinational pharmaceutical companies. Of these candidates, two, three, one, eight, seven, seven
and six are Approved or at Phase III, Phase II/III, Phase II, Phase I/II, Phase I or at the preclinical
stage, respectively.

This report provides a comprehensive review on the breast cancer immunotherapy pipeline and
presents summary clinical findings (pre-clinical to Phase III) on the candidates presented, including a
discussion of current biological strategies to develop new immunotherapies. These developments are
creating new partnering opportunities in this field.

Table of Contents:

Report Contents

Due to the nature of this report, details (name of candidate vaccine or therapeutic antibody, together
with their respective antigen or target) in this report contents page, have been omitted.
Executive Summary

Chapter 1 Background p.7

1. Breast Cancer
1.1 Statistics
1.2 Diagnosis
1.3 Staging
1.4 Current Treatments
1.5 This Report

Chapter 2 Breast Cancer Immunotherapy Strategies p.12

2.1 Vaccines & Antibodies

Chapter 3 Approved p.25

3.1   Summary
3.2   Approved Antibodies
3.3   Antibody, Approved
3.4   Antibody, Approved

Chapter 4 Phase III p.30

4.1   Summary
4.2   Phase III Vaccines and Antibodies
4.3   Antibody, Phase III
4.4   Antibody, Phase III
4.5   Vaccine, Phase III

More Related Reports :

 VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011

 Biomarkers in Alzheimers Disease, 2011

 Alzheimers Disease: Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011

 Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Breast Cancer Vaccines and Therapeutic Antibodies: Pipeline, 2011

 Alzheimers Disease Biomarkers in Cerebrospinal Fluid and Blood, 2011

 Image-Based Biomarkers in Alzheimers Disease, 2011

 Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Vaccines: Pipeline, Strategies and Clinical

 Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011


For More details about above & other Reports plz contact :

Vina

Aarkstore.com

Contact: Marketing team

Mob.No.918149852585

Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/

http://in.linkedin.com/in/aarkstore

http://www.facebook.com/aarkstore

http://www.aarkwebsolutions.com/

XML : http://www.aarkstore.com/feeds/Biopharmreports.xml

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:4
posted:2/18/2013
language:
pages:3